CA3241220A1 - Personalized cancer therapy targeting normally non-expressed sequences - Google Patents
Personalized cancer therapy targeting normally non-expressed sequences Download PDFInfo
- Publication number
- CA3241220A1 CA3241220A1 CA3241220A CA3241220A CA3241220A1 CA 3241220 A1 CA3241220 A1 CA 3241220A1 CA 3241220 A CA3241220 A CA 3241220A CA 3241220 A CA3241220 A CA 3241220A CA 3241220 A1 CA3241220 A1 CA 3241220A1
- Authority
- CA
- Canada
- Prior art keywords
- hsap38
- mmus38
- sequences
- tissue
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/30—Detection of binding sites or motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Primary Health Care (AREA)
- Public Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21215594.9 | 2021-12-17 | ||
| EP21215594 | 2021-12-17 | ||
| EP22187561.0 | 2022-07-28 | ||
| EP22187561 | 2022-07-28 | ||
| PCT/EP2022/086444 WO2023111306A1 (en) | 2021-12-17 | 2022-12-16 | Personalized cancer therapy targeting normally non-expressed sequences |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3241220A1 true CA3241220A1 (en) | 2023-06-22 |
Family
ID=84943771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3241220A Pending CA3241220A1 (en) | 2021-12-17 | 2022-12-16 | Personalized cancer therapy targeting normally non-expressed sequences |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250054576A1 (https=) |
| EP (1) | EP4449420A1 (https=) |
| JP (1) | JP2025500926A (https=) |
| AU (1) | AU2022409746B2 (https=) |
| CA (1) | CA3241220A1 (https=) |
| WO (1) | WO2023111306A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025158034A1 (en) | 2024-01-24 | 2025-07-31 | Evaxion Biotech A/S | Method for optimizing selection of an effective vaccine agent |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| CA3058807A1 (en) * | 2017-04-03 | 2018-10-11 | Biontech Us Inc. | Protein antigens and uses thereof |
| WO2020141207A1 (en) | 2019-01-03 | 2020-07-09 | Evaxion Biotech Aps | Vaccines targeting neoepitopes |
| US20220184191A1 (en) | 2019-03-11 | 2022-06-16 | Evaxion Biotech A/S | Nucleic acid vaccination using neo-epitope encoding constructs |
| EP3994156A1 (en) | 2019-07-05 | 2022-05-11 | The Francis Crick Institute Limited | Novel cancer antigens and methods |
| WO2021123232A1 (en) | 2019-12-18 | 2021-06-24 | Evaxion Biotech Aps | Nucleic acid vaccination using neo-epitope encoding constructs |
| IT202000006973A1 (it) * | 2020-04-02 | 2021-10-02 | Istituto Naz Tumori Irccs Fondazione G Pascale | Antigeni herv tumore-specifici e loro uso nella immunoterapia del cancro |
| US20230147574A1 (en) | 2020-04-07 | 2023-05-11 | Evaxion Biotech A/S | Neoepitope immunotherapy with APC targeting unit |
-
2022
- 2022-12-16 US US18/719,468 patent/US20250054576A1/en active Pending
- 2022-12-16 AU AU2022409746A patent/AU2022409746B2/en active Active
- 2022-12-16 WO PCT/EP2022/086444 patent/WO2023111306A1/en not_active Ceased
- 2022-12-16 CA CA3241220A patent/CA3241220A1/en active Pending
- 2022-12-16 JP JP2024536287A patent/JP2025500926A/ja active Pending
- 2022-12-16 EP EP22843138.3A patent/EP4449420A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025500926A (ja) | 2025-01-15 |
| US20250054576A1 (en) | 2025-02-13 |
| AU2022409746A1 (en) | 2024-07-04 |
| WO2023111306A1 (en) | 2023-06-22 |
| AU2022409746B2 (en) | 2025-12-04 |
| EP4449420A1 (en) | 2024-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022215196B2 (en) | Predicting T cell epitopes useful for vaccination | |
| JP7282834B2 (ja) | 共通ネオ抗原 | |
| JP7554119B2 (ja) | 共有抗原 | |
| US20210138056A1 (en) | Neoepitope vaccine compositions and methods of use thereof | |
| JP2015533473A (ja) | 個別のがんワクチン及び適応免疫細胞療法 | |
| JP2025157393A (ja) | Ｈｉｖ抗原及びｍｈｃ複合体 | |
| US20260094669A1 (en) | Epitope prediction via a learned genotype network across class ii mhc alleles | |
| KR20250031143A (ko) | 개인맞춤형 항암백신 개발을 위한 신항원 선정 방법 | |
| AU2022409746B2 (en) | Personalized cancer therapy targeting normally non-expressed sequences | |
| CN118974832A (zh) | 靶向正常非表达序列的个性化癌症疗法 | |
| HK40068529A (en) | Predicting t cell epitopes useful for vaccination | |
| CA2982971C (en) | Predicting t cell epitopes useful for vaccination | |
| WO2025158034A1 (en) | Method for optimizing selection of an effective vaccine agent | |
| CN116547761A (zh) | 用于制备含新肽的疫苗试剂的工艺 | |
| EA046410B1 (ru) | Иммуногенетическая скрининговая проба на рак | |
| HK1247989B (en) | Predicting t cell epitopes useful for vaccination | |
| HK1246852B (zh) | 预测可用於疫苗接种的t细胞表位 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20241118 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241127 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241127 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241127 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251124 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251124 |